RhumbLine Advisers
BHVN

RhumbLine Advisers’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

RhumbLine Advisers’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-94,287
Closed -$14.3M – 3092
2022
Q3 		$14.3M Buy
94,287
+14,804
+19% +$2.19M 0.02% 704
2022
Q2 		$11.6M Buy
79,483
+17,015
+27% +$2.17M 0.02% 830
2022
Q1 		$7.41M Sell
62,468
-1,344
-2% -$168K 0.01% 1096
2021
Q4 		$8.79M Sell
63,812
-347
-0.5% -$44.1K 0.01% 1055
2021
Q3 		$8.91M Buy
64,159
+2,421
+4% +$302K 0.01% 1022
2021
Q2 		$5.99M Buy
61,738
+9,861
+19% +$800K 0.01% 1330
2021
Q1 		$3.55M Sell
51,877
-6,890
-12% -$557K ﹤0.01% 1599
2020
Q4 		$5.04M Buy
58,767
+2,189
+4% +$185K 0.01% 1355
2020
Q3 		$3.68M Sell
56,578
-13,364
-19% -$876K 0.01% 1345
2020
Q2 		$5.11M Buy
69,942
+14,207
+25% +$756K 0.01% 1200
2020
Q1 		$1.9M Buy
55,735
+4,467
+9% +$204K ﹤0.01% 1577
2019
Q4 		$2.79M Buy
51,268
+3,229
+7% +$160K ﹤0.01% 1609
2019
Q3 		$2M Buy
48,039
+5,022
+12% +$212K ﹤0.01% 1747
2019
Q2 		$1.88M Buy
43,017
+3,377
+9% +$190K ﹤0.01% 1779
2019
Q1 		$2.04M Buy
39,640
+2,895
+8% +$125K ﹤0.01% 1701
2018
Q4 		$1.36M Buy
36,745
+12,587
+52% +$454K ﹤0.01% 1867
2018
Q3 		$907K Sell
24,158
-1,355
-5% -$49.8K ﹤0.01% 2041
2018
Q2 		$1.01M Sell
25,513
-2,420
-9% -$76.8K ﹤0.01% 2006
2018
Q1 		$720K Buy
27,933
+19,160
+218% +$573K ﹤0.01% 2077
2017
Q4 		$237K Sell
8,773
-1,787
-17% -$49.2K ﹤0.01% 2560
2017
Q3 		$395K Buy
10,560
+288
+3% +$8.74K ﹤0.01% 2436
2017
Q2 		$257K Buy
+10,272
New +$237K ﹤0.01% 2634

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $403M AUM 28.73% 1-Year Est. Return

RhumbLine Advisers's BHVN Position: Q4 2022 in Review

RhumbLine Advisers sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 94,287 shares — an estimated $14.3M sold.

RhumbLine Advisers first reported a position in BHVN in Q2 2017 and held it in 22 quarters. The position peaked at $14.3M in Q3 2022. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • RhumbLine Advisers reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • RhumbLine Advisers sold 94,287 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $14.3M.
  • RhumbLine Advisers first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2017 and held it in 22 quarters.
  • RhumbLine Advisers's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $14.3M in Q3 2022.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on RhumbLine Advisers's 13F filing for Q4 2022, filed 14 Feb 2023.